Related Experiment Video
Updated: Jul 11, 2026

Labeling Stem Cells with Ferumoxytol, an FDA-Approved Iron Oxide Nanoparticle
Published on: November 4, 2011
Abstract:
In patients with iron overload, oral deferasirox has a less favourable risk-benefit balance than subcutaneous deferoxamine: deferasirox appears to be less effective and also has more hepatic and renal adverse effects. In second-line situations it is better to first use deferiprone (another oral treatment, with which deferasirox has not been compared), a drug with which we have more experience. However, as iron chelation can be a lifelong necessity for some patients, deferasirox can be reserved as a third-line option which may be useful in some cases.
Related Concept Videos
Dosage Regimen: Fixed Dose
Fixed-dose regimens can be used for various routes of administration, including intravenous (IV) injections and oral medications. For IV administration, a predetermined amount of the drug is...
Drug Dosing: Obese Patients
Renal Failure: Dose Adjustments
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
Drugs for Treatment of Diarrhea-Predominant IBS
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Extracorporeal Removal of Drugs: Hemoperfusion and Hemofiltration
Heart Failure V: Medical Management
